MA47131A - Composés benzyl-amide phosphodiamide antiviraux - Google Patents
Composés benzyl-amide phosphodiamide antivirauxInfo
- Publication number
- MA47131A MA47131A MA047131A MA47131A MA47131A MA 47131 A MA47131 A MA 47131A MA 047131 A MA047131 A MA 047131A MA 47131 A MA47131 A MA 47131A MA 47131 A MA47131 A MA 47131A
- Authority
- MA
- Morocco
- Prior art keywords
- phosphodiamide
- amide
- benzyl
- antiviral compounds
- antiviral
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437745P | 2016-12-22 | 2016-12-22 | |
| US201762540748P | 2017-08-03 | 2017-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47131A true MA47131A (fr) | 2021-05-12 |
Family
ID=62627287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047131A MA47131A (fr) | 2016-12-22 | 2017-12-19 | Composés benzyl-amide phosphodiamide antiviraux |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11123355B2 (fr) |
| EP (1) | EP3558322B1 (fr) |
| JP (1) | JP2020504734A (fr) |
| KR (1) | KR20190100249A (fr) |
| CN (1) | CN110035760A (fr) |
| AU (1) | AU2017378893A1 (fr) |
| BR (1) | BR112019012511A2 (fr) |
| CA (1) | CA3046029A1 (fr) |
| MA (1) | MA47131A (fr) |
| MX (1) | MX2019007262A (fr) |
| RU (1) | RU2019122625A (fr) |
| WO (1) | WO2018118826A1 (fr) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017100108A1 (fr) | 2015-12-10 | 2017-06-15 | Merck Sharp & Dohme Corp. | Promédicaments antiviraux du ténofovir à base de phosphodiamide |
| US10450335B2 (en) | 2015-12-15 | 2019-10-22 | Merck Sharp & Dohme Corp. | Antiviral oxime phosphoramide compounds |
| WO2018039157A1 (fr) | 2016-08-25 | 2018-03-01 | Merck Sharp & Dohme Corp. | Promédicaments antiviraux du ténofovir |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| WO2018080903A1 (fr) | 2016-10-26 | 2018-05-03 | Merck Sharp & Dohme Corp. | Composés aryl-amide phosphodiamide antiviraux |
| KR20190100250A (ko) | 2016-12-22 | 2019-08-28 | 머크 샤프 앤드 돔 코포레이션 | 테노포비르의 항바이러스 지방족 에스테르 전구약물 |
| EP3558322B1 (fr) | 2016-12-22 | 2021-09-29 | Merck Sharp & Dohme Corp. | Composés benzyl-amide phosphodiamide antiviraux |
| JP7037667B2 (ja) | 2017-12-20 | 2022-03-16 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| WO2019195181A1 (fr) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Anticorps et leurs fragments qui se lient à la protéine x du virus de l'hépatite b |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| WO2019211799A1 (fr) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Analogue de dinucléotide 2'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle |
| EP3823629B1 (fr) | 2018-07-19 | 2024-12-25 | Merck Sharp & Dohme LLC | Promédicaments d'amide phosphinique de ténofovir |
| WO2020028097A1 (fr) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Formes solides d'acide (r)-11-(méthoxyméthyl)-12-(3-méthoxypropoxy)-3,3-diméthyl-8-0 x0-2,3,8,13b-tétrahydro-1h-pyrido[2,1-a] pyrrolo[1,2-c]phtalazine-7-carboxylique |
| EP4371987B9 (fr) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Composés de 6-azabenzimidazole substitués utilisés en tant qu'inhibiteurs de hpk1 |
| EP3873608A1 (fr) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1 |
| MX2021008751A (es) | 2019-01-25 | 2021-11-12 | Univ Brown | Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad. |
| WO2020178769A1 (fr) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Dinucléotides cycliques en 2'3' et leurs promédicaments |
| WO2020178768A1 (fr) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Analogue du dinucléotide 3'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle utilisé en tant que modulateur de sting |
| CN113574063B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 3’3’-环二核苷酸及其前药 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| CN114245807B (zh) | 2019-06-25 | 2025-05-02 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
| IL289925B2 (en) | 2019-07-27 | 2026-03-01 | Brii Biosciences Inc | A derivative of adenosine and a pharmaceutical preparation containing it |
| CN110441453B (zh) * | 2019-08-14 | 2022-03-15 | 国家烟草质量监督检验中心 | 一种分离检测磷胺异构体的方法 |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| HRP20241379T1 (hr) | 2019-09-30 | 2024-12-20 | Gilead Sciences, Inc. | Cjepiva za hbv i postupci za liječenje hbv |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| CN111157638A (zh) * | 2019-12-31 | 2020-05-15 | 济南康和医药科技有限公司 | 一种检测维生素c中草酸含量的方法 |
| KR102987126B1 (ko) | 2020-03-20 | 2026-07-07 | 길리애드 사이언시즈, 인코포레이티드 | 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법 |
| LT4192474T (lt) | 2020-08-07 | 2025-11-25 | Fosfonamidų nukleotidų analogų provaistai ir jų farmacinis panaudojimas | |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US20240269142A1 (en) | 2021-05-13 | 2024-08-15 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| EP4359413A1 (fr) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Composés de modulation de la diacylglycérol kinase |
| WO2023196832A2 (fr) * | 2022-04-06 | 2023-10-12 | Brii Biosciences, Inc. | Composition pharmaceutique et procédé de traitement d'infections par le virus de l'immunodéficience humaine |
| WO2025162234A1 (fr) * | 2024-01-29 | 2025-08-07 | Nanjing Zenshine Pharmaceuticals Co., Ltd. | Dérivés d'acide phosphorique et leur utilisation pharmaceutique |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240246A1 (fr) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Polythérapies avec de la ribavirine |
| TW202608468A (zh) | 2024-05-13 | 2026-03-01 | 美商基利科學股份有限公司 | 組合療法 |
| WO2025240242A1 (fr) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Polythérapies avec ribavirine |
| CN119080839B (zh) * | 2024-11-07 | 2025-03-11 | 上海柯君医药科技有限公司 | 一种抗病毒药物及其用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE486882T1 (de) | 1993-09-17 | 2010-11-15 | Gilead Sciences Inc | Nukleotidanaloge |
| US5977061A (en) | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| CN1740182A (zh) | 1999-12-22 | 2006-03-01 | 症变治疗公司 | 新的双氨基化膦酸酯前药 |
| HRP20030047B1 (hr) | 2000-07-21 | 2016-02-26 | Gilead Sciences, Inc. | Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava |
| US7388002B2 (en) | 2001-11-14 | 2008-06-17 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| PT1583542E (pt) | 2003-01-14 | 2008-09-17 | Gilead Sciences Inc | Composições e métodos para terapia de combinação antiviral |
| US7553825B2 (en) * | 2003-12-30 | 2009-06-30 | Gilead Sciences, Inc. | Anti-proliferative compounds, compositions, and methods of use thereof |
| EP1809277A2 (fr) | 2004-10-26 | 2007-07-25 | Inc. Gilead Sciences | Derives de phosphonate d'acide mycophenolique |
| WO2007002912A2 (fr) * | 2005-06-29 | 2007-01-04 | Gilead Sciences, Inc. | Composes anti-proliferatifs, compositions et leurs procedes d'utilisation |
| US8338593B2 (en) | 2006-07-07 | 2012-12-25 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
| TWI444384B (zh) | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
| TWI515000B (zh) | 2010-04-01 | 2016-01-01 | 伊迪尼克製藥公司 | 用於治療病毒感染之化合物及醫藥組合物 |
| US9120781B2 (en) | 2010-05-11 | 2015-09-01 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| US9243025B2 (en) | 2011-03-31 | 2016-01-26 | Idenix Pharmaceuticals, Llc | Compounds and pharmaceutical compositions for the treatment of viral infections |
| AP3639A (en) | 2011-08-16 | 2016-03-13 | Gilead Sciences Inc | Tenofovir alafenamide hemifumarate |
| CA2857490C (fr) | 2011-12-22 | 2020-03-31 | Geron Corporation | Analogues de guanine en tant que substrats de telomerase et affecteurs de la longueur de telomeres |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| CN103435672A (zh) * | 2013-04-25 | 2013-12-11 | 刘沛 | 含有取代苄基的新型核苷磷酸酯前药的结构与合成 |
| MX377983B (es) | 2014-09-15 | 2025-03-04 | Univ California | Análogos de nucleótidos. |
| WO2017007701A1 (fr) | 2015-07-07 | 2017-01-12 | Merck Sharp & Dohme Corp. | Composés antiviraux de phosphodiamide |
| WO2017027434A1 (fr) | 2015-08-10 | 2017-02-16 | Merck Sharp & Dohme Corp. | Composés phosphodiamide antiviraux d'ester d'acide bêta-aminé |
| CN106167504A (zh) | 2015-11-04 | 2016-11-30 | 洛阳聚慧医药科技有限公司 | 非环核苷磷酰胺d‑氨基酸酯衍生物及其盐的制备以及在抗病毒方面的应用 |
| WO2017100108A1 (fr) | 2015-12-10 | 2017-06-15 | Merck Sharp & Dohme Corp. | Promédicaments antiviraux du ténofovir à base de phosphodiamide |
| US10450335B2 (en) | 2015-12-15 | 2019-10-22 | Merck Sharp & Dohme Corp. | Antiviral oxime phosphoramide compounds |
| WO2018039157A1 (fr) | 2016-08-25 | 2018-03-01 | Merck Sharp & Dohme Corp. | Promédicaments antiviraux du ténofovir |
| WO2018080903A1 (fr) | 2016-10-26 | 2018-05-03 | Merck Sharp & Dohme Corp. | Composés aryl-amide phosphodiamide antiviraux |
| EP3558322B1 (fr) | 2016-12-22 | 2021-09-29 | Merck Sharp & Dohme Corp. | Composés benzyl-amide phosphodiamide antiviraux |
| KR20190100250A (ko) | 2016-12-22 | 2019-08-28 | 머크 샤프 앤드 돔 코포레이션 | 테노포비르의 항바이러스 지방족 에스테르 전구약물 |
-
2017
- 2017-12-19 EP EP17883867.8A patent/EP3558322B1/fr active Active
- 2017-12-19 AU AU2017378893A patent/AU2017378893A1/en not_active Abandoned
- 2017-12-19 MX MX2019007262A patent/MX2019007262A/es unknown
- 2017-12-19 RU RU2019122625A patent/RU2019122625A/ru not_active Application Discontinuation
- 2017-12-19 WO PCT/US2017/067159 patent/WO2018118826A1/fr not_active Ceased
- 2017-12-19 US US16/471,304 patent/US11123355B2/en active Active
- 2017-12-19 MA MA047131A patent/MA47131A/fr unknown
- 2017-12-19 CA CA3046029A patent/CA3046029A1/fr not_active Abandoned
- 2017-12-19 BR BR112019012511-6A patent/BR112019012511A2/pt not_active Application Discontinuation
- 2017-12-19 CN CN201780075193.9A patent/CN110035760A/zh active Pending
- 2017-12-19 JP JP2019533564A patent/JP2020504734A/ja active Pending
- 2017-12-19 KR KR1020197020681A patent/KR20190100249A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US11123355B2 (en) | 2021-09-21 |
| CN110035760A (zh) | 2019-07-19 |
| WO2018118826A1 (fr) | 2018-06-28 |
| RU2019122625A (ru) | 2021-01-22 |
| AU2017378893A1 (en) | 2019-05-16 |
| EP3558322B1 (fr) | 2021-09-29 |
| US20190321380A1 (en) | 2019-10-24 |
| EP3558322A1 (fr) | 2019-10-30 |
| MX2019007262A (es) | 2019-09-05 |
| BR112019012511A2 (pt) | 2019-11-19 |
| EP3558322A4 (fr) | 2020-05-06 |
| KR20190100249A (ko) | 2019-08-28 |
| JP2020504734A (ja) | 2020-02-13 |
| CA3046029A1 (fr) | 2018-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41614A (fr) | Composés antiviraux | |
| EP3720430A4 (fr) | Composés benzocarbonyle | |
| EP3691623A4 (fr) | Composés de benzosulfonyle | |
| EP3558322A4 (fr) | Composés benzyl-amide phosphodiamide antiviraux | |
| EP3532069A4 (fr) | Composés aryl-amide phosphodiamide antiviraux | |
| MA49701A (fr) | Composés immunomodulateurs | |
| EP3474845A4 (fr) | Composés immunomodulateurs | |
| MA42293A (fr) | Composés antibactériens | |
| MA44233A (fr) | Nouveaux composés | |
| MA44020A (fr) | Composés antitumoraux | |
| EP3523306A4 (fr) | Composés spirocycliques | |
| MA44050A (fr) | Nouveaux composés | |
| ME03419B (fr) | Composés dihydroisoquinolinone substitués | |
| EP3445750A4 (fr) | Composés thérapeutiques | |
| EP3436003A4 (fr) | Composés bicycliques antidiabétiques | |
| EP3464336A4 (fr) | Composés | |
| EP3450133A4 (fr) | Procédé de moulage par soufflage de liquide | |
| EP3728289A4 (fr) | Composés optimisés | |
| DK3558995T3 (da) | Polymorfer | |
| DK3558961T3 (da) | Polymorfer | |
| EP3390413A4 (fr) | Composés oximes phosphoramides antiviraux | |
| EP3709995A4 (fr) | Composés bicycliques antidiabétiques | |
| EP3668981A4 (fr) | Composés reversir tm réglables | |
| EP3310352A4 (fr) | Composés cristallins | |
| MA43799A (fr) | Composés de 2-oxindole |